NASDAQ : COEP
Coeptis Therapeutics Holdings, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 16.4 USD (Apr 24, 2026, 4:00 PM EDT) · Market cap 102.06M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 102.06M |
| Enterprise Value | 96.48M |
Dates
| Measure | Value |
|---|
| Earnings Date | May 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 6.22M |
| Shares Outstanding | 6.22M |
| Shares Change (YoY) | +120.03% |
| Shares Change (QoQ) | +13.71% |
| Owned by Insiders (%) | 14.40% |
| Owned by Institutions (%) | 9.04% |
| Float | 5.25M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 74.88 |
| Forward PS | n/a |
| PB Ratio | 6.95 |
| P/TBV Ratio | 8.07 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 70.79 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 4.16 |
| Quick Ratio | 3.60 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -20.30 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -136.90% |
| Return on Assets (ROA) | -65.05% |
| Return on Invested Capital (ROIC) | -83.17% |
| Return on Capital Employed (ROCE) | -90.67% |
| Weighted Average Cost of Capital (WACC) | 2.38% |
| Revenue Per Employee | $227,174 |
| Profits Per Employee | -$1.99M |
| Employee Count | 6 |
| Asset Turnover | 0.11 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -0.43 |
| 52-Week Price Change | +42.61% |
| 50-Day Moving Average | 12.26 |
| 200-Day Moving Average | 13.58 |
| Relative Strength Index (RSI) | 72.10 |
| Average Volume (20 Days) | 57,291 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 429,801 |
| Short Previous Month | 376,288 |
| Short % of Shares Out | 6.91% |
| Short % of Float | 8.18% |
| Short Ratio (days to cover) | 10.53 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 1.36M |
| Gross Profit | 1.18M |
| Operating Income | -13.04M |
| Pretax Income | -12.28M |
| Net Income | -11.92M |
| EBITDA | -11.86M |
| EBIT | -13.04M |
| Loss Per Share | -$2.81 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 6.35M |
| Total Debt | 268,875 |
| Net Cash | 6.08M |
| Net Cash Per Share | $0.98 |
| Equity (Book Value) | 14.07M |
| Book Value Per Share | 2.36 |
| Working Capital | 5.58M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -8.60M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 1.18M |
| Net Borrowing | 771,250 |
| Free Cash Flow | -8.60M |
| FCF Per Share | -$1.38 |
Margins
| Measure | Value |
|---|
| Gross Margin | 86.75% |
| Operating Margin | -956.94% |
| Pretax Margin | -900.72% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -120.03% |
| Shareholder Yield | -120.03% |
| Earnings Yield | -11.68% |
| FCF Yield | -8.43% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Dec 31, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 2.12 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |